Skip to main content

Amneal Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Feb 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 27, 2026

AMRX$21.28+5.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 27, 2026Amneal Pharmaceuticals, Inc.
By:/s/ Anastasios Konidaris
Anastasios Konidaris
Executive Vice President, Chief Financial Officer(Principal Financial and Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Chirag PatelPresident, Co-Chief Executive Officer and DirectorFebruary 27, 2026
Chirag Patel(Co-Principal Executive Officer)
/s/ Chintu PatelCo-Chief Executive Officer and DirectorFebruary 27, 2026
Chintu Patel(Co-Principal Executive Officer)
/s/ Anastasios KonidarisExecutive Vice President, Chief Financial OfficerFebruary 27, 2026
Anastasios Konidaris(Principal Financial and Accounting Officer)
/s/ Paul M. MeisterFebruary 27, 2026
Paul M. MeisterChairman of the Board and Director
/s/ Deb AutorFebruary 27, 2026
Deb AutorDirector
/s/ J. Kevin BuchiFebruary 27, 2026
J. Kevin BuchiDirector
/s/ Jeffrey P. GeorgeFebruary 27, 2026
Jeffrey P. GeorgeDirector
/s/ John J. Kiely, Jr.February 27, 2026
John J. Kiely, Jr.Director
/s/ Ted NarkFebruary 27, 2026
Ted NarkDirector
/s/ Gautam PatelFebruary 27, 2026
Gautam PatelDirector
/s/ Shlomo YanaiFebruary 27, 2026
Shlomo YanaiDirector
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.